Werbung
Werbung

BOLT

BOLT logo

Bolt Biotherapeutics, Inc. Common Stock

5.83
USD
Gesponsert
+0.02
+0.34%
09. Jan., 15:58 UTC -5
Geschlossen
exchange

Nach-Markt

5.64

-0.19
-3.26%

BOLT Ergebnisberichte

Positives Überraschungsverhältnis

BOLT übertreffen die 15 der letzten 20Schätzungen.

75%

Nächster Bericht

Datum des nächsten Berichts
23. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$680.00K
/
-$6.22
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-68.65%
/
+67.20%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
-18.16%

Bolt Biotherapeutics, Inc. Common Stock earnings per share and revenue

On 12. Nov. 2025, BOLT reported earnings of -3.72 USD per share (EPS) for Q3 25, beating the estimate of -5.90 USD, resulting in a 36.99% surprise. Revenue reached 2.17 million, compared to an expected 739.50 tausend, with a 193.31% difference. The market reacted with a +0.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -6.22 USD, with revenue projected to reach 680.00 tausend USD, implying an increase of 67.20% EPS, and decrease of -68.65% in Revenue from the last quarter.
FAQ
For Q3 2025, Bolt Biotherapeutics, Inc. Common Stock reported EPS of -$3.72, beating estimates by 36.99%, and revenue of $2.17M, 193.31% above expectations.
The stock price moved up 0.21%, changed from $4.69 before the earnings release to $4.70 the day after.
The next earning report is scheduled for 23. März 2026.
Based on 7 analysts, Bolt Biotherapeutics, Inc. Common Stock is expected to report EPS of -$6.22 and revenue of $680.00K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung